{"id":15724,"date":"2023-01-16T09:58:58","date_gmt":"2023-01-16T08:58:58","guid":{"rendered":"https:\/\/ggba.swiss\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/"},"modified":"2023-07-04T13:40:46","modified_gmt":"2023-07-04T11:40:46","slug":"geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/","title":{"rendered":"Geneva start-up STALICLA signs exclusive in-licensing agreement with Novartis"},"content":{"rendered":"\n<p><a href=\"https:\/\/stalicla.com\/\" target=\"_blank\" rel=\"noopener\">STALICLA<\/a>\u00a0is a precision molecular neuroscience clinical-stage biotech company, advancing the first precision medicine platform (DEPI) for patients with neurodevelopmental disorders (NDDs). DEPI, which has demonstrated proof-of-concept in other neurodevelopmental programs, has allowed for the identification of two distinct subgroups of patients with autism spectrum disorder and their tailored treatments STP1 and STP2. The two drugs are planned to enter Phase 2 clinical trials in 2023. STP1 and STP2 hold a multi-billion market potential.<\/p>\n<p>Based at the <a href=\"https:\/\/www.campusbiotech.ch\/\" target=\"_blank\" rel=\"noopener\">Campus Biotech<\/a>\u00a0in Geneva, the nearly six-year-old company has entered an exclusive in-license agreement with\u00a0<a href=\"https:\/\/www.novartis.com\/\" target=\"_blank\" rel=\"noopener\">Novartis<\/a>\u00a0to advance a late-stage drug candidate, mavoglurant (AFQ056), a selective non-allosteric metabotropic glutamate receptor 5 (mGluR5) antagonist. mGluR5 has been tied to mood disorders, addiction, and rare and common forms of Autism.<\/p>\n<p>Mavoglurant has previously been tested in more than 1,800 patients and demonstrated a good safety and tolerability profile. Following highly promising results from a Phase 2 study conducted with mavoglurant in cocaine-use disorder (CUD), STALICLA is now preparing to advance mavoglurant into Phase 3 development for the treatment of CUD.<\/p>\n<p>In parallel, STALICLA will leverage its precision neurobiology drug development platform (DEPI) to detect subgroups of high-responder patients with rare and common neurodevelopmental disorders where mavoglurant can be an effective treatment, as guided by earlier clinical studies.<\/p>\n<p>The market potential of the CUD and NDD indications alone could top EUR 2 billion globally.<\/p>\n<h4>A testament to the strength of STALICLA\u2019s neurobiology medicine platform<\/h4>\n<p>\u201cThis agreement with Novartis is a testament to the strength of our precision neurobiology medicine platform. We are excited about this transaction to further develop mavoglurant and bring it to the right patients,\u201d said Lynn Durham, STALICLA \u2019s CEO &amp; Founder.<\/p>\n<p>Under the terms of the agreement, STALICLA has acquired worldwide rights to mavoglurant for substance-use disorders, neurodevelopmental disorders, and other indications in exchange for upfront fees and equity, and development and commercial milestones of up USD 270 million, plus royalties on sales.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>STALICLA has acquired global rights for Novartis&#8217; drug candidate mavoglurant, a treatment for substance-use disorders and neurodevelopmental disorders, with an undisclosed upfront fee, equity, and up to USD 270 million in milestone payments.<\/p>\n","protected":false},"author":3,"featured_media":15725,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,902,911,886],"class_list":["post-15724","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-personalized-medicine","tag-pharma","tag-rd"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Geneva start-up STALICLA signs exclusive in-licensing agreement with Novartis - Greater Geneva Bern area<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Geneva start-up STALICLA signs exclusive in-licensing agreement with Novartis - Greater Geneva Bern area\" \/>\n<meta property=\"og:description\" content=\"STALICLA has acquired global rights for Novartis&#039; drug candidate mavoglurant, a treatment for substance-use disorders and neurodevelopmental disorders, with an undisclosed upfront fee, equity, and up to USD 270 million in milestone payments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-16T08:58:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-04T11:40:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-3.png\" \/>\n\t<meta property=\"og:image:width\" content=\"630\" \/>\n\t<meta property=\"og:image:height\" content=\"380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"mathieu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"mathieu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/\"},\"author\":{\"name\":\"mathieu\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"headline\":\"Geneva start-up STALICLA signs exclusive in-licensing agreement with Novartis\",\"datePublished\":\"2023-01-16T08:58:58+00:00\",\"dateModified\":\"2023-07-04T11:40:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/\"},\"wordCount\":323,\"image\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-3.png\",\"keywords\":[\"Biotech\",\"Personalized Medicine\",\"Pharma\",\"R&amp;D\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/\",\"name\":\"Geneva start-up STALICLA signs exclusive in-licensing agreement with Novartis - Greater Geneva Bern area\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-3.png\",\"datePublished\":\"2023-01-16T08:58:58+00:00\",\"dateModified\":\"2023-07-04T11:40:46+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"breadcrumb\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-3.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-3.png\",\"width\":630,\"height\":380},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Geneva start-up STALICLA signs exclusive in-licensing agreement with Novartis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\",\"name\":\"mathieu\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/mathieu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Geneva start-up STALICLA signs exclusive in-licensing agreement with Novartis - Greater Geneva Bern area","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/","og_locale":"en_US","og_type":"article","og_title":"Geneva start-up STALICLA signs exclusive in-licensing agreement with Novartis - Greater Geneva Bern area","og_description":"STALICLA has acquired global rights for Novartis' drug candidate mavoglurant, a treatment for substance-use disorders and neurodevelopmental disorders, with an undisclosed upfront fee, equity, and up to USD 270 million in milestone payments.","og_url":"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-01-16T08:58:58+00:00","article_modified_time":"2023-07-04T11:40:46+00:00","og_image":[{"width":630,"height":380,"url":"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-3.png","type":"image\/png"}],"author":"mathieu","twitter_card":"summary_large_image","twitter_misc":{"Written by":"mathieu","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/#article","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/"},"author":{"name":"mathieu","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"headline":"Geneva start-up STALICLA signs exclusive in-licensing agreement with Novartis","datePublished":"2023-01-16T08:58:58+00:00","dateModified":"2023-07-04T11:40:46+00:00","mainEntityOfPage":{"@id":"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/"},"wordCount":323,"image":{"@id":"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-3.png","keywords":["Biotech","Personalized Medicine","Pharma","R&amp;D"],"articleSection":["Life sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/","url":"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/","name":"Geneva start-up STALICLA signs exclusive in-licensing agreement with Novartis - Greater Geneva Bern area","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/#primaryimage"},"image":{"@id":"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-3.png","datePublished":"2023-01-16T08:58:58+00:00","dateModified":"2023-07-04T11:40:46+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"breadcrumb":{"@id":"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-3.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Stalicla-630x380-1-3.png","width":630,"height":380},{"@type":"BreadcrumbList","@id":"https:\/\/staging.ggba.swiss\/en\/geneva-start-up-stalicla-signs-exclusive-in-licensing-agreement-with-novartis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Geneva start-up STALICLA signs exclusive in-licensing agreement with Novartis"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab","name":"mathieu","url":"https:\/\/ggba.swiss\/en\/author\/mathieu\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/15724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=15724"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/15724\/revisions"}],"predecessor-version":[{"id":17302,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/15724\/revisions\/17302"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/15725"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=15724"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=15724"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=15724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}